Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Pharmacogenomics in Stroke: Feasibility of CYP2C19 Testing in Patients With Minor Stroke or High Risk TIA (CYP2C19 and Stroke)

NCT06943586 is registered in ClinicalTrials.gov with University of Alabama at Birmingham as lead sponsor.

NCT NCT06943586
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06943586 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Pharmacogenomics in Stroke: Feasibility of CYP2C19 Testing in Patients With Minor Stroke or High Risk TIA (CYP2C19 and Stroke)
Lead sponsor
University of Alabama at Birmingham
Phase
Not applicable
Overall status
Recruiting
Start date
April 9, 2025
Completion date
April 1, 2029
Enrollment
200 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

stroke, transient ischemic attack (tia)